No Data
No Data
Humacyte's Symvess Gains FDA Approval and Launches
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Summary
BTIG Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $8
Humacyte Shares Tumble 10% as Q4 Loss Narrows but Revenue Remains Elusive
BTIG Adjusts Price Target on Humacyte to $8 From $10, Maintains Buy Rating
8-K: Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update